Article
Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
The pharmacogenomics journal - 1 Aug 2011
Li J-L, Wang X-D, Chen S-Y, Liu L-S, Fu Q, Chen X, Teng L-C, Wang C-X, Huang M
Abstract excerpt
The impact of CYP3A5*3, a CYP3A5 nonexpresser genotype, on inhibitory effects of diltiazem on tacrolimus metabolism has not been assessed. In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively). Subsequently,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.